AstraZeneca’s real-world evidence (RWE) ZORA study shows the negative consequences of reducing or discontinuing life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalaemia (HK).
Historically, pharmaceutical, biotech, and MedTech business models could be summed up in two steps; the first was discovering and developing new innovative treatments through the R&D process, and the second was passing the baton to Commercial teams who would knock on the doors of prescribers to generate sales.
For anyone who has worked in life sciences for more than ten years, you will recognize that the ‘future of field forces’ has been a hot topic for some time. We seem to have gone through several phases of prediction, none of which have proven particularly reliable.
Preferences
Would you like to share some personal information with us so we can improve your experience on Researchalize.org?
